Early Conversion to Aflibercept for Persistent Diabetic Macular Edema Results in Better Visual Outcomes and Lower Treatment Costs

PURPOSE: To evaluate the functional and anatomic outcomes, as well as cost-effectiveness, of the timing of conversion to intravitreal aflibercept (IVA) in patients with treatment-resistant diabetic macular edema (DME). METHODS: Thirty consecutive eyes (25 patients) were identified that were treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramsey, David J, Poulin, Samuel J, LaMonica, Lauren C, Blaha, Gregory R, Barouch, Fina C, Chang, Jeffrey, Marx, Jeffrey L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802895/
https://www.ncbi.nlm.nih.gov/pubmed/33447009
http://dx.doi.org/10.2147/OPTH.S286665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802895/
https://www.ncbi.nlm.nih.gov/pubmed/33447009
http://dx.doi.org/10.2147/OPTH.S286665

Ejemplares similares